Pay in 4 interest-free payments of $5.60 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
Unfortunately, a phase II clinical trial of UBX0101 (NCT03513016) was completed in patients with osteoarthritis and the promising results observed (Table 1), in vitro and in vivo, have not been up to the expectations in treated patients, leading only to a decrease of pain, without a significant improvement of the disease 30
Shipping: Fast Sydney/Melbourne Dispatch via Australia Post Express Storage & Handling Store the lyophilised powder in a cool, dry place at a temperature below 25C, protected from light
Some patients tolerate one better than the otherthis is individual
Vella A, Bouatia-Naji N, Heude B, Cooper JD, Lowe CE, Petry C, Ring SM, Dunger DB, Todd JA, Ong KK
Subcutaneous injection produces rapid peak plasma concentrations within 1530 minutes followed by relatively quick clearance, potentially favoring more frequent administration
US$ 27.41
US$ 23.30
,aspect=ignore)
US$ 27.63
